Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your investment is really in the management.
A great team with a great product....
Or a soso team with a great product.
Which one do we have?
I strongly agree with you, BUT...
The reason it won't happen is Al would lose his $2m year
and the CEO and CFO would each lose their $1m+ per year.
They couldn't get away with taking out high
Incomes under your proposal.
Thats why it would never be considered.
You are thinking about share holders and company growth.
Sadly, they are not.
And I don't think Al even looks at the share price.
Terrible Afrezza promo was the plan.
That brings us here now where Sanofi has all the leverage
a year from now we'll all look on this day and wish we...
The market says 'no Sanofi deal in 2016'
And MNKD has no money and no choices.
They're All Wrong.
Just my opinion
I think Edstrom was canned because he tripled
Afrezza product manufacturing last summer
without first seeing the increase in orders.
He saw the bigger batch reduces
cost but Al saw it as stupid waste.
Genzyne (Sanofi diabeties div.) like Edstrom
and he was initially hired to seal the deal.
He's 65 and just wants another year (see yesterdays 8k). Thats gives Al some cushion
finding a CEO that can take MNKD to the next growth level.
I'm expecting some news about new
board members coming on the team.
We're also still waiting to hear an update on the 4 other
products to use the Technosphere inhaler.
That has been in the background, but no PR's yet.
That's the secret other reason Sanofi likes MNKD.
The pain management inhaler would be the biggest news.
Sanofi has 34 meds and inhalers for some of them
would make things easier for alot of patients.
That inhaler is a niche product covered by over
30 patents controlled by MNKD.
Food for thought.
All just my opinion.
Sanofi likes Edstrom, they don't like uncertainty with Al.
Things can move ahead now.
Al's age and his decision to give 90% to charity without
leaving a strong management team with financial resources at MNKD
creates uncertainty with Sanofi.
This is step one in closing deals for 2016.
I was expecting this.
small guys are selling and big guys quietly buying
Many odd lots selling and big blocks on the buy side.
So Al is just going to let MNKD fail
After putting $1.7 b and ten years into this?
Why Sanofi will renew for 2016
They are offering the same worldwide exclusive deal with
Lexicon for their oral diabetic drug.
Thats not approved until mid-late 2016.
( if it gets approved)
Sanofi PR about that offer came out Nov2015
That stock will likely then be hit with short sellers for the same reason MNKD has been.
Many don't want it to succeed cause it rocks the current very profitable diabetic boat.
Sanofi wants this market and is covering all areas.
They don't want to lose world wide Afrezza especially after
Europe/China and everyone else is approved for sales.
What if the Lexicon oral isn't approved/delayed and they
drop Afrezza...then they end up with nothing except their
current losing market share.
I think alot of biotech's are watching this.
Some hoping this fails and others hoping the
Sanofi license isn't renewed so they can come in.
Al Mann is getting phone calls one one side and
making calls for CEO's on the other side.
My guess is a biotech company placing one of their
VP's in as a CEO in with Al can make great things happen.
Maybe Sanofi will do that?
Otherwise I see the Sanofi exclusivity the problem.
AND Yes, we would all like to scoop up more shares on and big dips!
...well maybe not all here
Sorry to say but i agree with you
Good post Martin, well said and just right.
I see the product as awesome
But I see those managing This product at Mannkind as 'disappointing'.
It's hard to get the eye of the tiger about something if you already
are a billionare and gets $2m a year no matter how the product does.
Then the CFO getting $1m year even if nothing happens.
The previous CEO helped get Afrezza/Sanofi deal and now he's a liability.
They have alot to do in getting a real team here.
Just my thoughts.
The buy side blocks are getting bigger.
Someone is getting worried this will shoot
up and these prices will be a memory.
Someone bought 1.7m shares today
Alot of formT int'l buying starting to come in
Whats up with that?
Afrezza had a year with no issues. It's the real deal.
Most large companies don't add a new medicine until it's been out a year.
That way any risk or side effects can be caught early.
The second year is when the growth happens
If everything the first year goes well.
Sanofi mentioned upfront the Afezza growth will be slow initially.
Another buy opportunity here folks $2.00
It's just coming down for support. It's fine.
I am a newbuyer here at $2.
Martin caused MNKD many FDA delays and adding
burn cash problems that MNKD has today.
I see many PR's coming out over the next couple months.
Trend is down, but $2 shows strong support.
Look at the 10 year history.
MNKD always does reversal abouts now.
And here we are again.
Today were looking for support, everything is fine.
Please be kind, it's easy to see the 'shorts' here.
One good CEO PR and the shorts will lose it all.
Thats all it takes and that can come at any time with the 8k.
My thoughts exactly
Sanofi selling Laggard for $12b, buying MNKD?
That may be the only way to make this work.
Al Mann doesn't like to do PR's and that uncertainly helps drive down the stock.
Then feedback at Glassdoor
employees from Mannkind would like management to have clear
goals and vision so a change is definitly needed here.
Martin's gone, his tweets show he's attacking everyone else right now.
Al just came back as CEO. Martin Shkreli wants the job
and he's been bad mouthing MNKD to drive shares down
just so he can short shares and scoop up the company later.
Thats what he posted last year.
He even contacted the FDA about potential
risks just to slow down Afrezza approval.
Martin is MNKD biggest problem.
Now that he has KBIO he may be gone from here.
Just Google Mannkind + Martin Shkreli
It's there
Maybe SNY wanted it this way.Poor Sales
to help drive Mannkind down so any buyout looks good.
I don't believe it works like that, plus both
SNY and MNKD CEO's from last year are long gone now.
Going up on small volume -sellers are gone
If MNKD breaks $2.20 today then $2.50 is next.
We're almost there.
The $2.20 resistance looks easy.
The $2.50 resistance may be harder but the whippy
price today may send it higher very fast.
If we touch $2.25 today I'll be happy.
Why SNY won't terminate Afrezza 2016....
Afrezza is the future.
Plus MNKD has 4 other types of medicine for inhalers in the works.
SNY would lose that too.
SNY is afraid somesome else can come in take over all licensing
and then they have to compete with Afrezza after
it becomes more popular than injections.
MNKD may choose to license it to several companies
under their own trademark brand names.
There are lots of ways this can go and if SNY loses
AFrezza control they may never get another chance.
Mannkind Breakout Coming!
Looks like MNKD may gap up tomorrow
SNY is moving to 3 main product divisions in Jan.
to better focus on their core groups.
The diabeties group will likely make the decision about Mannkind
with the final decision from Oliver (SNY CEO)
If they can influence the CEO choice for MNKD
then that is a very good thing.
It still all comes down to Al Mann and by now he is ready to admit
it's time to get someone with the eye of the tiger to come in and make it happen.
All my opinion and $5 looks very do-able.
Other news is coming too.
Afrezza in UK/ Europe can be announced at any time.
They were wrapping up the stage3 trials.
Approval is the next step.
The new CEO can be announced at any time!
The Afrezza story is just beginning.
Dropping too fast, i'm staying out for now.
I said i'll be back at and buying at .002
Then said I'll be back at .0016.
Nothing looks good here right now.
now i say i'm just watching.
I'm here because the $2 support has held for 10 years.
It's been here many times and this has always been
a good place to buy MNKD.
January's have always been good for Mannkind.
A quick dip to $1.75 or lower also brings in alot of buying so I'm okay.
Our new gang in Israel can read charts and will see this too.
48% short interest, 120m shares.
All terrible news pending.
This is a great opportunity!
Why SNY will renew... Fear another competitor will swoop in, do better
product presentations/marketing and make Afrezza very profitable.
Then they get the approvals for Europe, Japan, Canada and more.